Skip to content

SBIR Phase 2 Guide: Awards & How to Apply (2026)

Updated 13 official sources

Quick Answer: SBIR Phase 2 awards run up to $1,250,000 at NSF and carry a $2,239,578 guideline at NIH, typically funding about 2 years of prototype development and commercialization work; other agencies set amounts in each solicitation.

Full answer and how we checked it

You generally need a Phase 1 award first, unless an agency offers a Direct to Phase II pathway. SBIR was reauthorized in April 2026 through September 30, 2031, after a lapse that began October 1, 2025. The commercialization plan is the single biggest differentiator in Phase 2 reviews.

Who this is for: Small businesses that have completed (or are finishing) an SBIR Phase 1 award and want to understand what Phase 2 requires, how it differs from Phase 1, and how to write a competitive proposal.

Data note: NSF and NIH award amounts come from the current NSF solicitation and NIH SBIR guidelines. Other agencies set Phase 2 amounts in each solicitation, so check the current one. Program parameters may change with appropriations and the 2026 reauthorization.

Source review by Grantsights, June 3, 2026: We rechecked SBIR.gov, SBA policy materials, NIH SEED, NSF Phase II awardee guidance, DOD SBIR/STTR materials, DOE, NASA, USDA, and USASpending award records. Where official sources stop: Phase II is agency-specific: NSF limits standard Phase II to recent Phase I awardees, allows one proposal per Phase I award, and lists up to $1,250,000 for up to 24 months, while NIH, DOD, DOE, NASA, and USDA use different ceilings, timing, and Direct to Phase II rules.

In this guide

Quick Facts

Agency
HHS
Deadline
Check official source
Status
Upcoming

Assistance Listing 93.395: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.395, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
3,308
Avg Award (whole listing)
$3,837,757
Median Award (whole listing)
$1,827,310
Total Funding (FY2024, whole listing)
$1.1B
YoY Funding Trend
+1.2%

Data last verified: April 8, 2026

You've survived the hardest part of the SBIR program: winning Phase 1. Now you're staring at the SBIR Phase 2 application, and it's a different animal. Phase 1 asked "can this work?" Phase 2 asks "can you build it, and will anyone buy it?" The award amounts are 4 to 10 times larger, the proposals are longer, and reviewers expect real data instead of hypotheses.

If you're weighing your options across agencies, check our SBIR agencies comparison guide first. Here's the good news: you're competing against a smaller, pre-screened pool of companies that already proved feasibility. Agencies publish success rates at different levels of detail, so check the agency's own data (NIH posts SBIR success rates on NIH RePORT (opens in a new tab)) rather than relying on a general figure.

The bad news? The proposal is harder to write, the commercialization plan matters more than the science, and each agency runs Phase 2 differently.

2026 Status: Lapse and Reauthorization

SBIR and STTR authority lapsed on October 1, 2025. Congress reauthorized both programs in P.L. 119-83, signed April 13, 2026, through September 30, 2031. The law adds per-company limits on proposals starting in FY2027, and HHS limits a company to 9 applications per year (NOT-OD-26-090 (opens in a new tab)). It also created a Strategic Breakthrough award for Phase II awardees. According to NSF 26-510 (opens in a new tab), posted May 22, 2026, NSF accepts Strategic Breakthrough proposals of up to $30,000,000 only on invitation from the cognizant program officer.

Grantsights checked the NSF solicitation against the NSF Phase IIB supplement page and NIH's current SBIR guidelines in October 2026, and the amounts in this guide reflect those sources. To see which agencies have SBIR solicitations open now, use the free Grantsights grant search.


SBIR Phase 2 Award Amounts by Agency

Award sizes vary substantially across agencies. Here's what you can expect in 2026:

AgencyPhase 2 Award AmountDurationNotes
NIH$2,239,578 guidelineTypically 2 yearsPhase I guideline is $335,937
NSFUp to $1,250,000Typically 24 monthsIncludes fee and TABA; Phase IIB can add up to $500,000
DOD (general)Set by component and topicVariesNavy, Army, Air Force differ
DOESet in the annual solicitationVariesCheck the topic
NASASet in the annual solicitationVariesCheck the current solicitation
USDASet in the annual RFAVariesCheck the current RFA

Know whether your number is a cap or a guideline. According to NSF 26-510 (opens in a new tab), NSF's $1,250,000 is the maximum and already includes the small business fee and optional TABA funding. NIH's $2,239,578 is a guideline, and the current NIH SBIR NOFO explains when a budget can differ. For DOD, DOE, NASA, and USDA, the solicitation and topic set the limit. Don't guess. Call your program manager and ask.

Budget structure matters. Phase 2 budgets need to show clear progression from research to development. Reviewers get skeptical when 80% of the budget is personnel and 5% is materials. If you're building a prototype, your budget should reflect equipment, materials, testing, and manufacturing costs. A budget that looks identical to Phase 1 suggests you haven't thought through what development actually requires.


SBIR Phase 2 Eligibility: What You Need to Qualify

The baseline eligibility requirements for SBIR Phase 2 are straightforward but strict:

  • Completed Phase 1. You must have a Phase 1 award from the same agency (with rare exceptions). "Completed" means you've submitted your final report and the agency has accepted your Phase 1 results.
  • Small business status. Your company must still qualify as a small business under SBA rules: fewer than 500 employees, organized for profit, more than 50% owned by U.S. citizens or permanent residents, and the primary place of employment must be in the United States.
  • Principal investigator employment. Your PI must be primarily employed by your company (more than 50% of their time) at the time of award. Your company also needs to be registered on SAM.gov with an active UEI number. This is the rule that catches academic founders who haven't made the jump from their university lab.
  • Research performance. You must perform a minimum percentage of the work in-house: 50% for SBIR, 40% for STTR. Subcontracting the rest is fine, but you can't be a shell company that farms everything out.

The Phase 1 to Phase 2 Timeline

Each agency handles the Phase 1 to Phase 2 transition differently:

NIH gives you the most flexibility. You submit your Phase 2 application to a standard SBIR due date; check the current NIH SBIR NOFO for any timing limits after Phase 1. There's no invitation required. You submit through NIH ASSIST (opens in a new tab) like any other NIH application.

NSF doesn't use invitations for Phase II. According to NSF 26-510 (opens in a new tab), only NSF Phase I awardees can submit a Phase II proposal, and it must go in between 6 and 24 months after the start date of the Phase I award, through Research.gov (opens in a new tab). Invitations apply to Phase I and Fast-Track, which start with a Project Pitch.

DOD varies wildly by component. Some DOD agencies run annual Phase 2 solicitations where you respond to specific topics. Others accept Phase 2 proposals on a rolling basis tied to your Phase 1 topic. Check your specific component's process, because the Navy runs differently from the Air Force, and DARPA runs differently from both.

DOE posts Phase 2 topics in an annual solicitation, usually in the fall. You submit through the DOE SBIR/STTR Exchange (opens in a new tab). DOE evaluates Phase 2 proposals against new criteria, not just your Phase 1 performance. A strong Phase 1 outcome doesn't guarantee a Phase 2 invitation.


How Reviewers Evaluate SBIR Phase 2 Differently from Phase 1

This is where most applicants stumble. They write their Phase 2 proposal the same way they wrote Phase 1, just longer. That's a mistake.

Phase 1 vs. Phase 2 Review Emphasis

Review CriterionPhase 1 WeightPhase 2 Weight
Technical merit / innovationHighMedium-High
Team qualificationsMediumMedium
Commercialization potentialLow-MediumHigh
Phase 1 results / feasibility dataN/AHigh
Budget justificationLowMedium

Commercialization is the biggest shift. In Phase 1, reviewers accept a one-page commercialization section that says "we'll explore market opportunities." In Phase 2, that section needs to be 5 to 10 pages of specific customers, revenue models, competitive positioning, regulatory timelines, and manufacturing plans. At NIH, the commercialization plan is weighted as heavily as the research plan. At NSF, it's even more prominent.

Your Phase 1 data is under a microscope. Reviewers will read your Phase 1 final report alongside your Phase 2 proposal. They're looking for three things: did you accomplish what you proposed, do the results support the Phase 2 plan, and are you honest about what didn't work. Overstating Phase 1 results is the fastest way to lose reviewer trust. If an experiment failed, explain what you learned and how it changed your approach.

The bar for innovation drops slightly. Phase 1 is all about novelty and risk. Phase 2 is about execution. Reviewers care less about whether your idea is novel and more about whether you can actually build it. Show engineering plans, prototype designs, testing protocols, and manufacturing pathways. Make the reviewers believe you can deliver a product.

What Reviewers Actually Look For

Here's what separates funded from unfunded Phase 2 proposals:

Funded proposals present Phase 1 data in clear figures and tables, not buried in paragraphs. They have specific milestones for each 6-month period. They name 3 to 5 potential customers and include at least one letter of support from someone who'd actually buy the product. Their budget reflects a shift from research to development.

Unfunded proposals repeat Phase 1 aims with minor modifications. They use vague language about "exploring" and "investigating" instead of "building" and "testing." Their commercialization plan describes a market without naming a customer. Their timeline is a single Gantt chart with no intermediate decision points.


The Commercialization Plan: What Gets Funded

The commercialization plan is where Phase 2 proposals succeed or fail. Here's what a winning plan includes:

Customer Discovery Evidence

Don't tell reviewers about your Total Addressable Market. Tell them about the 15 customer discovery interviews you conducted during Phase 1. Name the companies (with their permission), describe their pain points, and explain why your solution fits. Letters of intent or pilot agreements are worth more than any market analysis.

Competitive Analysis That's Honest

Every reviewer will Google your competitors during the review. If your competitive analysis ignores obvious competitors or dismisses them without substance, you'll lose credibility. Acknowledge competitors' strengths, then explain specifically why your approach is better for your target segment. Use a comparison table.

Revenue Model with Real Numbers

Show unit economics. What does it cost you to produce one unit? What will you charge? What's your margin? If you're SaaS, show your customer acquisition cost assumptions and lifetime value calculations. Reviewers don't expect perfection, but they expect you've thought about whether this business makes money.

Regulatory Pathway

If your technology needs FDA clearance, EPA approval, or any other regulatory step, map it out. Which pathway (510(k), De Novo, PMA)? What's the timeline? What does it cost? What predicate devices exist? Ignoring regulatory requirements in a Phase 2 proposal tells reviewers you haven't thought past the lab.


Sequential Phase II: Getting a Second Phase 2 Award

Some agencies allow "sequential" or "competing continuation" Phase 2 awards. This means you can apply for a second Phase 2 funding cycle if your first Phase 2 produced strong results but you need more development time before commercialization.

NIH is the most generous here. You can apply for a Competing Continuation (Type 2) Phase 2 with the same budget and timeline as the original Phase 2. NIH also runs the Commercialization Accelerator Program (CAP) (opens in a new tab), which provides business training and technical assistance to awardees, not additional award funding.

NSF offers Phase IIB supplements of up to $500,000, limited to 50% of qualified third-party funds, according to the NSF Phase IIB supplement page (opens in a new tab). You need at least $100,000 in third-party commitments to qualify, and $1,000,000 in outside funds to reach the full $500,000.

DOD has component-specific sequential Phase 2 programs. Some components offer Phase II Enhancement funding that matches outside investment; check your component's current terms and ratio.

Sequential funding is underused. Many companies assume they need to move to Phase 3 (private investment) after one Phase 2. If your technology needs more development, ask your program manager about sequential options before you start fundraising.


Direct to Phase II: Skipping Phase 1

Several agencies offer Direct to Phase II (D2P2) pathways for companies that have already completed feasibility work using non-SBIR funding.

AgencyD2P2 Available?Requirements
NIHYesSubmit feasibility data equivalent to Phase 1 results
DODYesVaries by component; must demonstrate Phase 1 equivalence
DOEYesMust show completed feasibility study
NASAYesLimited topics; must demonstrate prior work
NSFNoOffers Fast-Track (by invitation after a Project Pitch) instead
USDANoMust complete Phase 1 first

D2P2 is harder than it sounds. The feasibility data requirement is strict. You need to show that you spent real money (your own funds, investor capital, or other grants) conducting Phase 1 equivalent research, and that your results match what a Phase 1 would have produced. Reviewers evaluate your feasibility data as if it were a Phase 1 final report. Incomplete or weak feasibility evidence is the top reason D2P2 proposals fail.

When D2P2 makes sense: You've already built a working prototype using venture funding or corporate R&D dollars. You have clear feasibility data. You don't want to wait 12 to 18 months for a Phase 1 cycle before applying for Phase 2. Companies with prior SBIR experience at other agencies are strong D2P2 candidates.


SBIR Phase 2 Enhancement Supplements

Phase 2 Enhancement programs provide additional funding to Phase 2 awardees who attract third-party investment. They're designed to bridge the gap between government-funded R&D and commercial viability.

NIH's CAP and other options. NIH's Commercialization Accelerator Program (CAP) provides mentoring and business development training, not award dollars. Extra funding for later-stage work comes through separate mechanisms, such as administrative supplements or specific NOFOs, when NIH offers them. Check NIH SEED (opens in a new tab) for what's open now.

NSF Phase IIB. NSF's enhancement program adds up to $500,000, limited to 50% of qualified third-party funds. If you raise $500,000 from an investor, NSF can provide up to $250,000; reaching the full $500,000 takes $1,000,000 in outside funds. The investor doesn't need to be a VC firm; it can be a strategic corporate partner, an angel group, or even a customer prepayment. NSF is flexible on the investment source but strict on verification.

DOD Phase II Enhancement. Several DOD components offer matching supplements tied to outside investment, with caps and ratios that differ by component and year. Check your component's current SBIR instructions before you plan around a match.

These programs are some of the best deals in the SBIR ecosystem. You're getting matching dollars from the government for investment you'd be raising anyway. If you're a Phase 2 awardee raising capital, check whether your agency offers enhancement funding before closing your round.


Building Your Phase 2 Timeline

A realistic Phase 2 timeline spans 24 months and should include clear decision gates:

Months 1 to 6: Detailed Design and Early Prototyping. Finalize specifications based on Phase 1 results. Begin component-level prototyping. Start long-lead procurement for materials and equipment. Begin formal customer engagement.

Months 7 to 12: System Integration and Initial Testing. Assemble integrated prototype. Conduct internal testing against specifications. Iterate on design based on test results. Present preliminary results to program manager at mid-project review.

Months 13 to 18: Validation and External Testing. Conduct testing with potential end users. Collect performance data for regulatory submissions if applicable. Begin manufacturing process development. Update commercialization plan with real feedback.

Months 19 to 24: Pre-Commercial Preparation. Complete reliability and durability testing. Finalize manufacturing plans and cost models. Execute pilot agreements with lead customers. Prepare for Phase 3 (private investment) or sequential Phase 2.

Include go/no-go decision points. Reviewers want to see that you'll pivot or stop if the data doesn't support continuation. A proposal that commits to 24 months of work regardless of results looks naive. Build in quarterly milestones with specific success criteria.


What SBA.gov Doesn't Tell You

The SBA's SBIR/STTR website (opens in a new tab) gives you program basics, solicitation links, and award data. Here's what it doesn't cover.

Your Phase 1 program officer is your most important Phase 2 resource. Before you write a single word of your Phase 2 proposal, call your Phase 1 program officer. They've read your Phase 1 final report. They know what the review panel thought of your work. They can tell you whether your Phase 2 plan aligns with the agency's priorities. Many program officers will make time for a short call if you ask. Skipping it is a common mistake.

Some Phase 2 budgets have more room than others. NSF's $1,250,000 is a hard maximum. NIH's $2,239,578 is a guideline, so a budget above it needs the program officer's input and a strong case under the current NOFO. But you need to justify every dollar above the guideline amount, and "because the project costs more" isn't justification. Show specifically what additional work the additional funding enables.

The gap between Phase 1 and Phase 2 kills more companies than bad proposals. Phase 1 ends, you spend months writing Phase 2, then you wait months for review and award. That's 12 to 18 months where your company might have no SBIR revenue. Plan for this gap before Phase 1 ends. Apply for bridge funding, line up consulting work, or raise a small angel round to keep your team intact. Companies that lose their technical team during the gap rarely win Phase 2.

Phase 2 reviews are less anonymous than you think. Review panels at most agencies discuss proposals out loud. Your company name, your PI's publication record, and your Phase 1 performance are all known to reviewers. Past reputation matters. If your Phase 1 final report was sloppy or late, that impression carries into Phase 2 review.


What USASpending.gov Shows for "SBIR Phase 2" Awards

A search of FY2025 USASpending.gov (opens in a new tab) award descriptions containing "SBIR Phase 2" found 18 awards totaling $21.3M. This is a keyword search, not a program-filtered count, so it captures only awards whose descriptions use that phrase and may include awards that aren't SBIR (Battelle, for example, isn't an SBIR-eligible small business). Treat it as a sample, not a total.

MetricAmount
Total awards18
Total funding$21,318,352
Average award$1,184,353
Median award$844,576

Top Recipients

RecipientTotal FundingAwards
CITY LABS, INC.$3,368,9901
LIFORDI IMMUNOTHERAPEUTICS, INC.$2,959,5571
VASCULONICS INC$2,354,0981
BATTELLE MEMORIAL INSTITUTE$2,328,9001
ALLERDIA INC$2,031,2141
BIOTHERAPEUTICS, INC.$1,854,3421
PROMEDIX, INC.$1,144,7581
TAXIS PHARMACEUTICALS INC$1,000,0001
VIMAAN ROBOTICS, INC.$1,000,0001
ALTAY THERAPEUTICS, INC$997,7753

Data source: USASpending.gov FY2025 award description search, accessed 2026-04-04.


Sources

Award data for this program

Largest awards active in FY2024

One row per recipient, its largest award | 3,308 Assistance Listing records | Avg: $3.8M

REAL DATA
1

Public Health Institute

CA

$333.7M
2

Sloan-Kettering Institute for Cancer Research

NY

$250.8M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Frequently Asked Questions

What is the difference between SBIR Phase 1 and Phase 2?

SBIR Phase 1 is a feasibility study. NSF funds Phase I up to $305,000 for 6 to 18 months, and NIH's Phase I guideline is $335,937. It tests whether your idea works. SBIR Phase 2 is the full research and development phase, typically about 2 years. NSF funds Phase II up to $1,250,000, and NIH's Phase II guideline is $2,239,578; other agencies set amounts in each solicitation. Phase 2 expects you to build a working prototype or near-commercial product based on your Phase 1 results. Reviewers in Phase 2 weight your commercialization plan much more heavily than in Phase 1, and they expect real data, not projections.

Can I apply for SBIR Phase 2 without completing Phase 1?

Some agencies offer Direct to Phase II (D2P2) programs that let you skip Phase 1 if you can demonstrate equivalent feasibility work using non-SBIR funding. NIH, DOD, and DOE all have D2P2 options, though the bar is high. You'll need to prove that you already completed the research that Phase 1 would have funded, using your own money, investor capital, or other grants. NSF does not offer Direct to Phase II; it offers Fast-Track instead.

How long does it take to get an SBIR Phase 2 award after Phase 1 ends?

Timelines vary by agency. NIH accepts Phase 2 applications on its standard SBIR due dates; check the current NIH SBIR NOFO for any timing limits. NSF doesn't require an invitation for Phase II: NSF Phase I awardees submit their Phase II proposal between 6 and 24 months after the Phase I start date. DOD components vary widely, with some accepting Phase 2 proposals on a rolling basis and others running annual solicitations. From Phase 2 submission to award notification, expect 4 to 9 months depending on the agency and review cycle.

What is an SBIR Phase 2 Enhancement supplement?

Phase 2 Enhancement (also called Phase IIB at some agencies) provides additional funding to Phase 2 awardees who secure third-party investment. NSF's Phase IIB provides up to $500,000 in new NSF funding, limited to 50% of qualified third-party funds, with at least $100,000 in third-party commitments required. So $500,000 from NSF takes $1,000,000 in outside funds. Some DOD components run their own enhancement programs. NIH's Commercialization Accelerator Program (CAP) is business training and technical assistance, not extra award funding. These supplements are designed to bridge the gap between research and commercialization.

What makes a strong SBIR Phase 2 commercialization plan?

Reviewers want specifics, not aspirational projections. A strong commercialization plan names your first 3 to 5 target customers and explains why they'd buy. It includes letters of intent or pilot agreements from potential customers, a realistic pricing model based on competitive analysis, a clear regulatory pathway with timeline, and specific milestones for each year of the Phase 2 period. Weak plans use phrases like 'large addressable market' without naming a single customer. The best plans show that someone has already paid for or committed to your technology.

Last updated November 4, 2026. Corrected November 4, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.